SANA - Sana Biotechnology, Inc. Stock Price, Fair Value and News

8.45USD-0.10 (-1.17%)Delayed as of 17 May 2024, 12:04 pm ET

Market Summary

USD8.45-0.10

Delayedas of 17 May 2024, 12:04 pm

-1.17%

SANA Stock Price

View Fullscreen

SANA RSI Chart

SANA Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-6.14

Price/Free Cashflow

-6.92

SANA Price/Earnings (Trailing)

SANA Profitability

Return on Equity

-82.26%

Return on Assets

-45.29%

Free Cashflow Yield

-14.45%

SANA Fundamentals

SANA Earnings

Earnings (TTM)

-308.6M

Earnings Growth (Yr)

-30.87%

Earnings Growth (Qtr)

-21.97%

Breaking Down SANA Revenue

52 Week Range

3.518.59

(Low)(High)

Last 7 days

14.0%

Last 30 days

1.7%

Last 90 days

-1.5%

Trailing 12 Months

14.3%

How does SANA drawdown profile look like?

SANA Financial Health

Current Ratio

6.07

SANA Investor Care

Shares Dilution (1Y)

15.67%

Diluted EPS (TTM)

-1.53

Tracking the Latest Insider Buys and Sells of Sana Biotechnology, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2024	bishop hans edgar	acquired	-	-	2,774	-
Mar 08, 2024	yang patrick y	sold	-236,300	9.452	-25,000	-
Feb 08, 2024	arch venture fund x, l.p.	bought	6,000,000	5.5	1,090,910	-
Feb 08, 2024	nelsen robert	bought	6,000,000	5.5	1,090,910	-
Feb 08, 2024	crandell keith	bought	6,000,000	5.5	1,090,910	-
Jan 05, 2024	bishop hans edgar	acquired	-	-	4,901	-
Jan 05, 2024	wilderotter mary agnes	acquired	-	-	1,470	-
Dec 15, 2023	hordo christian	sold	-300,098	4.0013	-75,000	evp, chief business officer
Oct 05, 2023	wilderotter mary agnes	acquired	-	-	2,077	-
Oct 05, 2023	bishop hans edgar	acquired	-	-	6,925	-

Which funds bought or sold SANA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	HarbourVest Partners LLC	sold off	-100	-480,192	-	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	2.71	5,140,170	8,527,760	-%
May 15, 2024	SUVRETTA CAPITAL MANAGEMENT, LLC	sold off	-100	-6,552,710	-	-%
May 15, 2024	Virtus ETF Advisers LLC	reduced	-6.42	122,472	217,140	0.12%
May 15, 2024	JANUS HENDERSON GROUP PLC	added	0.03	178,391	301,325	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	sold off	-100	-722,160	-	-%
May 15, 2024	Integral Health Asset Management, LLC	new	-	9,800,000	9,800,000	0.91%
May 15, 2024	T. Rowe Price Investment Management, Inc.	new	-	48,019,000	48,019,000	0.03%
May 15, 2024	UBS ASSET MANAGEMENT AMERICAS LLC	added	27.67	567,115	833,470	-%
May 15, 2024	Woodline Partners LP	added	31.4	6,198,990	8,990,500	0.08%

Are Funds Buying or Selling SANA?

Are funds buying SANA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SANA

No. of Funds

Unveiling Sana Biotechnology, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 03, 2024	fmr llc	-	0	SC 13G/A
Mar 07, 2024	baillie gifford & co	4.70%	10,360,620	SC 13G/A
Feb 14, 2024	flagship ventures fund v, l.p.	0.5%	1,035,208	SC 13G/A
Feb 09, 2024	arch venture fund ix, l.p.	22.3%	44,042,500	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 26, 2024	baillie gifford & co	5.15%	10,150,017	SC 13G/A
Apr 26, 2023	fmr llc	-	0	SC 13G
Feb 13, 2023	arch venture fund ix, l.p.	23.1%	44,042,500	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Jan 20, 2023	baillie gifford & co	5.64%	10,764,727	SC 13G/A

Recent SEC filings of Sana Biotechnology, Inc.

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 08, 2024	S-8	Employee Benefits Plan
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 18, 2024	8-K	Current Report
Apr 08, 2024	3	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 03, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Sana Biotechnology, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Sana Biotechnology, Inc. News

Latest updates

Sana Biotechnology, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	20.5%	681	565	631	707	747	823	898	971	1,048	1,129	1,233	1,260	1,304	730
Current Assets	50.5%	321	214	280	339	370	444	500	494	523	558	613	860	967	384
Cash Equivalents	35.5%	181	134	168	174	160	177	174	205	197	253	442	677	753	127
Net PPE	15.5%	82.00	71.00	68.00	63.00	64.00	67.00	67.00	68.00	69.00	65.00	63.00	59.00	51.00	47.00
Goodwill	0%	141	141	141	141	141	141	141	141	141	141	141	141	141	141
Liabilities	10.2%	306	278	266	352	319	323	332	332	346	401	403	354	422	299
Current Liabilities	-18.0%	53.00	64.00	67.00	112	103	112	115	97.00	94.00	99.00	92.00	43.00	35.00	31.00
Shareholder's Equity	30.5%	375	288	366	355	428	499	566	640	702	729	830	906	882	-
Retained Earnings	-11.2%	-1,445	-1,300	-1,249	-1,300	-1,100	-1,054	-974	-889	-816	-785	-674	-591	-610	-429
Additional Paid-In Capital	12.0%	1,821	1,626	1,616	1,607	1,567	1,558	1,547	1,535	1,524	1,515	1,505	1,497	1,492	8.00
Shares Outstanding	11.8%	221	198	197	197	191	191	188	188	186	166	161	180	-	-
Float	-	-	-	-	600	-	-	-	1,200	-	-	-	3,700	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-26.3%	-65,632	-51,959	-63,550	-58,801	-79,272	-76,067	-64,796	-71,478	-77,709	-110,099	-50,486	-40,556	-49,913	-37,559	-37,510	-33,366	-29,547	-
Share Based Compensation	14.6%	9,092	7,931	9,003	9,848	8,751	10,591	10,080	9,911	7,755	7,313	5,950	4,941	4,158	2,791	1,166	1,116	755	-
Cashflow From Investing	-604.4%	-77,228	15,310	51,348	42,627	62,727	88,428	31,859	77,730	12,545	-73,661	-185,904	-35,324	49,091	13,041	-268,313	-36,472	39,181	-
Cashflow From Financing	10749.7%	186,397	1,718	187	29,505	236	1,061	1,621	1,579	652	3,119	1,596	333	626,703	103	4.00	435,578	2.00	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SANA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 56,448	$ 67,166
Research and development related success payments and contingent consideration	38,007	120
General and administrative	16,269	16,766
Total operating expenses	110,724	84,052
Loss from operations	(110,724)	(84,052)
Interest income, net	3,034	1,976
Other income (expense), net	215	(47)
Net loss	$ (107,475)	$ (82,123)
Net loss per common share - basic	$ (0.49)	$ (0.43)
Net loss per common share - diluted	$ (0.49)	$ (0.43)
Weighted-average number of common shares - basic	217,290	191,228
Weighted-average number of common shares - diluted	217,290	191,228

SANA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 177,054	$ 133,517
Marketable securities	134,028	71,678
Restricted cash	3,832	3,832
Prepaid expenses and other current assets	6,349	4,488
Total current assets	321,263	213,515
Property and equipment, net	81,649	70,689
Operating lease right-of-use assets	71,565	74,903
Intangible asset	59,195	59,195
Goodwill	140,627	140,627
Other non-current assets	7,078	6,370
TOTAL ASSETS	681,377	565,299
Current liabilities:
Accounts payable	6,095	4,108
Accrued compensation	13,965	23,722
Accrued expenses and other current liabilities	19,674	23,462
Operating lease liabilities	13,167	13,195
Total current liabilities	52,901	64,487
Operating lease liabilities, net of current portion	92,922	90,901
Contingent consideration, net of current portion	114,990	109,606
Success payment liabilities	45,422	12,799
Total liabilities	306,235	277,793
Commitments and contingencies (Note 9)
Stockholders' equity:
Preferred stock, $0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value; 750,000 shares authorized; 221,286 and 197,857 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	22	20
Additional paid-in capital	1,820,701	1,625,637
Accumulated other comprehensive loss	(15)	(60)
Accumulated deficit	(1,445,566)	(1,338,091)
Total stockholders' equity	375,142	287,506
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 681,377	$ 565,299

About Sana Biotechnology, Inc.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG299 and SG242 that targets CD19+ cancer cells in patients with non-Hodgkin Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL); SG221 and SG239 for the treatment of multiple myeloma; and SG233, a CD22 CAR for the treatment of NHL, CLL, and ALL. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255, a B cell maturation antigen directed allogeneic CAR T for multiple myeloma; SC45, the PSC-derived pancreatic islet cells for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, Huntington's disease, and other astrocytic diseases. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is based in Seattle, Washington.

CEO	Dr. Steven D. Harr M.D.
WEBSITE	sana.com
INDUSTRY	Biotechnology
EMPLOYEES	424

Sana Biotechnology, Inc. Frequently Asked Questions

What is the ticker symbol for Sana Biotechnology, Inc.? What does SANA stand for in stocks?

SANA is the stock ticker symbol of Sana Biotechnology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sana Biotechnology, Inc. (SANA)?

As of Thu May 16 2024, market cap of Sana Biotechnology, Inc. is 1.89 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SANA stock?

You can check SANA's fair value in chart for subscribers.

What is the fair value of SANA stock?

You can check SANA's fair value in chart for subscribers. The fair value of Sana Biotechnology, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sana Biotechnology, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SANA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sana Biotechnology, Inc. a good stock to buy?

The fair value guage provides a quick view whether SANA is over valued or under valued. Whether Sana Biotechnology, Inc. is cheap or expensive depends on the assumptions which impact Sana Biotechnology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SANA.